HIGHLIGHTS
- who: Chuli Song and colleagues from the Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China have published the Article: Conformational Essentials Responsible for Neurotoxicity of A42 Aggregates Revealed by Antibodies against Oligomeric A42, in the Journal: Molecules 2022, 27, 6751. of /2022/
- future: In the near future anti-Au03b2 scFv antibodies will open a window of hope for patients with AD. On 7 June 2021 aducanumab became the first FDA-approved new drug for AD treatment in 18 years but a new randomized controlled trial is still . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.